MTOR and cancer: Although clinically approved agents such as rapamycin, plays a therapeutic role in cancer therapy (Opipari et al., 2004; Hoyer-Hansen et al., 2005; Kondo et al., 2005; Chang et al., 2007; Law et al., 2010, 2014; Yang et al., 2011; Wong et al., 2013), mTOR inhibition has adverse effects in protein synthesis, cell proliferation, and immune function (Levine and Kroemer, 2008; Pallet and Legendre, 2013).